sponsored
PatientsVille.com Logo

PatientsVille

Armodafinil Medical Research Studies

Up-to-date List of Armodafinil Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Armodafinil Medical Research Studies

Rank Status Study
1 Unknown  Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies
Conditions: Parkinsons Disease;   Lewy Bodies Disease
Intervention: Drug: Armodafinil
Outcome Measure: EGI netstation software (Electrical Geodesics Inc.) and a custom made software that runs on the Matlab platform (The Mathworks)
2 Recruiting The Nuvigil and Provigil Pregnancy Registry
Conditions: Narcolepsy;   Obstructive Sleep Apnea;   Shift Work Sleep Disorder
Intervention: Drug: Modafinil/Armodafinil
Outcome Measures: Overall pregnancy outcome;   Adverse fetal outcomes or congenital anomalies;   Congenital defects reported;   Adverse pregnancy and neonatal outcomes
3 Recruiting A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer
Condition: Esophageal Cancer
Interventions: Drug: Armodafinil;   Other: Placebo;   Drug: Minocycline;   Behavioral: Questionnaires
Outcome Measure: Mean Symptom Increase During Chemoradiation Therapy
4 Recruiting Modafinil, DRD4 Genotype and Cocaine Relapse
Condition: Cocaine Dependence
Intervention: Drug: Modafinil
Outcome Measure: Cocaine self-administration
5 Recruiting Cognitive Behavioral Therapy With or Without Armodafinil in Treating Cancer Survivors With Insomnia and Fatigue After Chemotherapy
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Procedure: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Placebo;   Procedure: Fatigue Assessment and Management;   Procedure: Sleep Disorder Therapy;   Drug: Armodafinil;   Procedure: Quality-of-life assessment;   Procedure: Management of Therapy;   Procedure: Sleep disorder therapy;   Procedure: cognitive assessment;   Procedure: Quality of Life assessment;   Procedure: Fatigue assessment and management;   Procedure: Management of therapy and complications;   Procedure: Cognitive Assessment;   Procedure: Quality of Life Assessment;   Procedure: Fatifue assessment and management
Outcome Measures: Severity of insomnia as assessed by the insomnia severity index and daily sleeep diaries.;   Fatigue as assessed by the brief fatigue index;   Adverse Events;   Fatigue as assessed by the functional assessment of chronic illness therapy-fatigue;   Sleep latency, wake after sleep onset, and total sleep time
6 Recruiting Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
Condition: Narcolepsy
Intervention: Drug: Armodafinil
Outcome Measures: Maximum observed plasma drug concentration (Cmax) by inspection;   Time to maximum observed plasma drug concentration (tmax) by inspection;   Area under the plasma drug concentration by time curve from time 0 to infinity;   Area under the plasma drug concentration by time curve from time 0 to the time of the last measurable drug concentration;   Terminal half-life;   Terminal elimination rate constant;   Apparent total plasma clearance;   Apparent volume of distribution;   Predicted accumulation ratio;   Maximum observed plasma drug concentration (Cmax);   Time to maximum observed plasma drug concentration;   AUC over 1 dosing interval;   AUC 0-t;   Observed accumulation ratio;   Steady-state accumulation ratio;   Mean sleep latency;   Clinical Global Impression of Change (CGI-C)
7 Recruiting Effect of Nuvigil on Fatigue
Condition: Menopause
Intervention: Drug: Armodafinil
Outcome Measures: Menopause Quality Of Life Questionnaire (MENQOL) Physical subscale;   Brief Fatigue Inventory (BFI);   Sleepiness;   Hot flash frequency and severity;   Anxiety symptoms;   Depressive symptoms;   Cognitive problems
8 Recruiting Single Agent Armodafinil for Patient-Reported Fatigue
Conditions: Head And Neck Cancer;   Fatigue
Interventions: Drug: Armodafinil;   Other: Placebo;   Behavioral: Questionnaires
Outcome Measure: Combined Patient-Reported Fatigue Scores
9 Recruiting Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Fatigue
Interventions: Drug: Armodafinil 150 mg;   Other: Placebo;   Drug: Armodafinil 250 mg
Outcome Measures: Response rate in terms of a clinically meaningful improvement in patient-reported fatigue at 8 weeks. A response is defined as an improvement of 2 points on the 0-10 scale of the usual fatigue on the Brief Fatigue Inventory (BFI).;   Fatigue: Brief Fatigue Inventory (BFI), Patient Reported Outcomes - Common Terminology Criteria for Adverse Events (PRO-CTCAE) and the summated score from the Patient Reported Outcomes Measurement Information System (PROMIS);   Cognitive function: As Assessed by Symbol Digit Modalities Test (SDMT), Controlled Oral Word Association, Trail Making Test, and the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog);   Quality of Life as measured by Linear Analogue Self Assessment (LASA);   Proportion of patients reporting adverse events via the CTCAE version 4.0 items
10 Recruiting Modafinil and Cognitive Function in POTS
Condition: Postural Tachycardia Syndrome
Interventions: Drug: Placebo;   Drug: Modafinil;   Drug: Propranolol
Outcome Measures: Visual Attention Performance Speed;   Stroop Test of Executive Function
11 Recruiting Modafinil in the Treatment of PTSD (Posttraumatic Stress Disorder)
Condition: Posttraumatic Stress Disorder
Intervention: Drug: Modafinil
Outcome Measures: Clinician Administered PTSD Scale (CAPS);   eye-gaze tracking to facial stimuli;   Modified Stroop;   event related potentials
12 Recruiting Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study
Conditions: Healthy;   Substance-related Disorder;   Mood Disorder
Interventions: Drug: Methylphenidate;   Drug: Modafinil;   Drug: MDMA;   Drug: Placebo
Outcome Measures: Effect on amygdala and striatum BOLD signal responses to emotional stimuli;   Effects on cognitive performance and associated BOLD signal changes in frontal areas;   Subjective effects;   Neuroendocrine effects;   Empathy and social behavior;   Physiological effects of methylphenidate, modafinil, and MDMA;   Genetic Polymorphisms;   Pharmacokinetics of methylphenidate, modafinil, and MDMA
13 Recruiting Palliative Morphine With or Without Concurrent Modafinil
Conditions: Cancer;   Pain Palliation;   Excessive Sleepiness
Interventions: Drug: Modafinil;   Drug: Placebo
Outcome Measures: Patient reported sleepiness scores;   Mood changes
14 Recruiting Treatment of Post Stroke Fatigue With a Wakefulness Promoting Agent
Conditions: Stroke;   Post Stroke Fatigue
Interventions: Drug: modafinil;   Drug: placebo
Outcome Measures: Multidimensional Fatigue Inventory (MFI- 20);   MFI-20;   Fatigue severity scale (FSS);   FSS
15 Recruiting A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia
Conditions: Nocturia;   Daytime Sleepiness
Intervention: Drug: Armodafinil 50 - 250 mg pills
Outcome Measures: Change in Epworth Sleepiness Scale;   Clinical Global Impressions, change in severity of excessive daytime sleepiness (EDS);   Number of naps;   Number of minutes napped based on sleep diary
16 Unknown  Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder
Conditions: Schizophrenia;   Cognition;   Obesity;   Sedation
Intervention: Drug: modafinil
Outcome Measures: Cognitive changes as measured by the NIH MCCB MATRICS;   Sedation and weight changes
17 Recruiting Treating Sleep and Cognitive Problems in Bipolar Disorder
Condition: Bipolar Disorder
Interventions: Drug: Modafinil;   Drug: Placebo
Outcome Measures: safety of adjunctive modafinil;   MCCB;   sleep quality;   UPSA;   QoL;   Vital signs;   Electrocardiogram;   liver function tests;   chemistry panel;   Complete blood count;   urinalysis;   Suicide risk scale;   Medication log
18 Recruiting Modafinil, Sleep Architecture and Cocaine Relapse
Condition: Cocaine Dependence
Interventions: Drug: Modafinil;   Behavioral: Cognitive Behavioral Therapy
Outcome Measures: Number of cocaine-free urines;   Polysomnographically measured sleep
19 Recruiting Modafinil Versus Placebo for Hypoactive Delirium in the Critically Ill
Conditions: Delirium;   Respiratory Failure
Intervention: Drug: Modafinil
Outcome Measures: Decreased CAM positive days in the ICU;   Length of stay in the ICU
20 Recruiting Armodafinil in Binge Eating Disorder (BED)
Conditions: Binge Eating Disorder;   Overweight;   Obese
Interventions: Drug: Armodafinil;   Drug: Matching placebo
Outcome Measure: The primary efficacy variable is binge day frequency as assessed by take-home patient diary

These studies may lead to new treatments and are adding insight into Armodafinil etiology and treatment.

A major focus of Armodafinil research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Armodafinil